HomeCompareCLVSF vs EQR

CLVSF vs EQR: Dividend Comparison 2026

CLVSF yields 1.63% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $18.4K in total portfolio value
10 years
CLVSF
CLVSF
● Live price
1.63%
Share price
$16.14
Annual div
$0.26
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$180.86
Full CLVSF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — CLVSF vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVSFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVSF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVSF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVSF
Annual income on $10K today (after 15% tax)
$138.35/yr
After 10yr DRIP, annual income (after tax)
$153.73/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $3,092.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVSF + EQR for your $10,000?

CLVSF: 50%EQR: 50%
100% EQR50/50100% CLVSF
Portfolio after 10yr
$31.3K
Annual income
$2,000.23/yr
Blended yield
6.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CLVSF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
12.3
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVSF buys
0
EQR buys
0
No recent congressional trades found for CLVSF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVSFEQR
Forward yield1.63%4.73%
Annual dividend / share$0.26$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$22.0K$40.5K
Annual income after 10y$180.86$3,819.61
Total dividends collected$1.7K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: CLVSF vs EQR ($10,000, DRIP)

YearCLVSF PortfolioCLVSF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,863$162.76$11,248$547.57$385.00EQR
2$11,788$165.24$12,701$666.53$913.00EQR
3$12,781$167.59$14,405$814.59$1.6KEQR
4$13,846$169.82$16,413$999.84$2.6KEQR
5$14,987$171.92$18,795$1,232.92$3.8KEQR
6$16,210$173.92$21,639$1,527.95$5.4KEQR
7$17,520$175.81$25,057$1,903.80$7.5KEQR
8$18,924$177.59$29,197$2,385.87$10.3KEQR
9$20,428$179.27$34,250$3,008.70$13.8KEQR
10$22,039$180.86$40,467$3,819.61$18.4KEQR

CLVSF vs EQR: Complete Analysis 2026

CLVSFStock

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

Full CLVSF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CLVSF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVSF vs SCHDCLVSF vs JEPICLVSF vs OCLVSF vs KOCLVSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.